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Aims: To estimate the social-economic costs of Type 1 Diabetes Mellitus (T1DM) in patients
aged 0–17 years in Spain from a social perspective.
Methods: We conducted a cross-sectional observational study in 2014 of 275 T1DM pediatric
outpatients distributed across 12 public health centers in Spain. Data on demographic and
clinical characteristics, healthcare utilization and informal care were collected from med-
ical records and questionnaires completed by clinicians and patients’ caregivers.
Results: A valid sample of 249 individuals was analyzed. The average annual cost for a
T1DM patient was €27,274. Direct healthcare costs were €4070 and direct non-healthcare
cost were €23,204. Informal (familial) care represented 83% of total cost, followed by med-
ical material (8%), outpatient and primary care visits (3.1%) and insulin (2.1%). Direct
healthcare cost per patient statistically differed by glycated haemoglobin (HbA1c) level
[mean cost €4704 in HbA1c 7.5% (58 mmol/mol) group vs. €3616 in HbA1c < 7.5%
(<58 mmol/mol) group)]; and by the presence or absence of complications and comorbidi-
ties (mean cost €5713 in group with complications or comorbidities vs. €3636 in group with-
out complications or comorbidities).
Conclusions: T1DM amongst pediatric patients incurs in considerable societal costs. Infor-
mal care represents the largest cost category.
 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Epidemiologic studies suggest that the incidence rate of type
1 diabetes mellitus has been growing worldwide, especially
amongst young children [1]. In Spain, the prevalence of type
1 diabetes is 1.1–1.44 per 1000 people under 15, with annual
incidence rates of between 11.5 and 27.6 per 100,000 people
in children under 15 [2].
Along with health effects, type 1 diabetes in the pediatric
population has a major economic impact for patients, health
services and society in general, for several reasons. First,
these patients take insulin-replacement therapies throughout
their lifetimes. Second, the disease entails a high risk of hos-
pitalization due to severe hypoglycemic or ketoacidosis
events as well as type 1 diabetes associated illnesses [3].
Third, the time dedicated to childcare because of diabetes
can be considerable. In these cases, the burden of care and
the opportunity cost of time spent on informal care can be
a highly relevant cost from the perspective of society [4].
Moreover, families are also likely to spend extra resources
(on drugs, private medical visits, monitoring systems, home
education, sport activities, transport, etc.) due to the disease
[5,6]. Lastly, as any chronic illness, type 1 diabetes may impact
negatively on several dimensions of children parents’ well-
being [5,7].
Measuring the social costs of type 1 diabetes in children is
a rather uncommon practice. However, it may be relevant for
healthcare decision-makers, as it provides useful information
to assess the real magnitude of the benefits of different inter-
vention programs that target the disease. Moreover, it offers a
baseline for planning prevention policies in relation to future
complications and for allocating health and social care and
research resources. Finally, it provides essential evidence
and information as regards the performance of new treat-
ments for the disease or any of its complications in economic
evaluations.
In Spain, the National Health System guarantees universal
coverage, free of charge to anyone living in Spain. Even if pri-
vate healthcare is available, if not all, close to 100% of patients
with type 1 diabetes are treated by the National Health Sys-
tem. The core package includes public health services, phar-
maceuticals, out-patient health services (primary and
specialized health care) and in-patient services. These ser-
vices are fully publicly funded and co-payment for the user
is zero, except for prescribed medicines. As all patients with
a chronic or life threatening condition, type 1 diabetes
patients pay a 10% co-payment for outpatient prescribed
medicines, with a maximum co-payment of 4.46€ per
prescription.
The objective of this study was to estimate the direct
healthcare costs and the direct non-healthcare costs
(including informal care) of type 1 diabetes in patients aged
0–17 years old in the outpatient setting during 2014 in
Spain.2. Subjects
The CHRYSTAL (Costs and Health Related qualitYof life Study
for Type 1 diAbetes meLlitus pediatric patients in Spain) study
is a multicenter, cross-sectional observational study of pedi-
atric population (0–17 years of age) diagnosed with type 1 dia-
betes who receive outpatient care by the Spanish public
healthcare system in pediatric endocrinology specialized cen-
ters within the hospital area, as is customary to treat type 1
diabetes pediatric outpatients in Spain.
Children with type 1 diabetes in Spain may be treated in
large centers (treating at least 150 diabetes pediatric patients),
medium centers (treating 50–149 diabetes pediatric patients)
and small centers (treating 49 diabetes pediatric patients or
less) [8]. In order to obtain a representative sample of type 1
diabetes children and adolescents as they are being treated
in Spain, a three-stage stratified sampling was carried out.
In the first stage, a randomized sample representative of 0–
17 years old population diagnosed with type 1 diabetes at
the national level (n = 275, 90% confidence level, 5% sampling
error) was collected based on the prevalence of type 1 dia-
betes in the population under 18 in Spain. In the second stage,
three age group quotas (0–5, 6–11, 12–17 years old) were estab-
lished within the sample in order to represent different age
groups of prevalence in Spain [9]. In parallel, we grouped
the Autonomous Communities of Spain into 8 regions based
on population size and proximity: Madrid, Catalonia, North-
west (Galicia, Asturias, Cantabria, Castilla y Leo´n), North (Ara-
go´n, Navarra, La Rioja, Paı´s Vasco), East (Valencia, Baleares),
Center (Castilla-la Mancha, Extremadura), South (Andalucı´a,
Murcia, Ceuta, Melilla), and Canary Islands. In the third stage,
we randomly selected 12 centers across these regions, out of a
list of 90 public hospitals in Spain that are known to provide
care to at least 20 type 1 diabetes patients under the age of
18 [8]. Selected centers were representative of the distribution
of center sizes per region, which allows accounting for any
differences in resource availability (such as number of beds,
medical or nursing staff and medical equipment) that may
be associated with center size, and for possible variations in
clinical practice across geographical regions. The number of
patients to enroll and age quotaswere assigned to each center
trying to replicate the previously described distribution of
pediatric patients with type 1 diabetes in Spain in large, med-
ium, and small centers [8]. Inclusion criteria were patients
under 18 years of age who had been diagnosed with type 1
diabetes for at least 12 months, implying that the youngest
age group under study was actually limited to children 1–
5 years of age. Patients diagnosed with any other type of
diabetes, patients participating in clinical trials and inpa-
tients, were excluded. Each center selected patients fulfilling
inclusion criteria as they were attending their previously
scheduled usual appointments until all age quotas were
completed.
The patient0s primary caregivers (defined as the adult
responsible for controlling the patient’s diabetes most of the
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fidentiality. The primary caregivers and patients 12 years old
and over provided their informed assent to participate in
the study and to release information, according to the Span-
ish legislation, and the study was approved by the hospitals0
Ethics Committees in accordance with national and regional
regulations.
3. Materials and methods
3.1. Data collection
Data were collected between March and August 2014, at one
single time for each patient, by the investigators of each cen-
ter (pediatric endocrinologists or diabetes specialist nurses). A
Case Report Form (CRF) was completed by clinical experts
using the patient0s medical record and one questionnaire
was filled by the patient0s primary caregiver (‘‘Caregiver’s
Questionnaire”). Data covered the 12-month period prior to
the date of collection. In order to minimize recall bias some
data were collected for the previous month, 3 months or
6 months, depending on the frequency of use of each
resource, and extrapolated to 12 months in order to obtain
annual costs.
The CRF included patient0s demographics (sex, age, height,
weight), date of first insulin injection, puberty status, HbA1c
level, diabetes related acute and chronic complications (hypo-
glycaemia, ketosis without acidosis, ketoacidosis, dawn phe-
nomenon, retinopathy, nephropathy and peripheral
neuropathy) and common comorbidities (hypothyroidism
and celiac disease), and healthcare resource utilization
related to diabetes (medication, outpatient visits, hospitaliza-
tions, emergency services, and medical tests).
The caregiver0s questionnaire included utilization of dia-
betes related medical material and supplies (glucose meters,
insulin injection pumps, glucose monitoring sensors, lancets,
blood strips), visits to private healthcare providers, caregiver0s
socio-demographic data (age, sex, level of education, occupa-
tion), extra expenditures due to diabetes (on transportation,
food, and sports activities), time devoted to diabetes surveil-
lance activities both by the primary caregiver and by other
caregivers, work status, and work problems associated to pro-
viding informal care.
3.2. Cost methodology
We estimated direct healthcare costs (those borne by the
Spanish National Health System), and direct non-healthcare
costs (out of pocket expenditures borne by families, and cost
equivalence of the time devoted to caregiving). We used a
prevalence approach to value health and social resources
consumed during a given year. This includes all healthcare
resources used to control the disease and to treat its compli-
cations, familial (informal) care and other non-healthcare
resources employed within a whole year. This approach is
particularly relevant when estimating the burden of chronic
conditions requiring long-term treatment [9–12]. We used a
bottom-up costing approach to estimate average annual costs
per patient [13]. The base year for all costs was 2014.3.3. Direct healthcare costs
Direct healthcare costs included medications related to dia-
betes or diabetes derived conditions (insulin and other medi-
cations), medical tests, outpatient and primary healthcare
visits, acute hospitalizations due to type 1 diabetes, medical
material and supplies, and use of emergency services.
The cost of insulin was calculated as cost per average daily
dose according to the patient0s information registered on his/
her notebook in the past three months and extrapolated to
12 months. The cost of insulin was also calculated by the
caregivers’ recall using the number of vials and pens that they
collected from the pharmacy. Given that the latter is subject
to recall bias, in the calculation of total costs we opted for a
conservative approach and considered the cost of insulin
according to average daily dose used. The annual cost of other
drugs was calculated according to medical records and the
regimen followed by the patient (dose, frequency, and days
of treatment in the past 12 months). All drug costs were
obtained from the list of approved drugs in Spain [14]. Official
price discounts published by the Spanish Ministry of Health
were applied [15].
The cost of healthcare resources (other than medication)
used by patients was calculated by multiplying resource
quantities by the average of all available official regional unit
costs [16]. Hospitalization costs were obtained by their main
Diagnosis-Related Group in Spain [17].
3.4. Direct non-healthcare costs
Direct non-healthcare costs include the costs of families0
expenditure on transportation, special food (e.g. carbohydrate
dietary supplements), physical activities undertaken because
of the child0s diabetes, and informal care provided by the pri-
mary and other caregivers. Informal care was defined as the
performance of tasks that help maintain or enhance the
patient0s health, carried out by non-professional caregivers
[18]. The primary caregiver was defined as the person who
carried out these tasks the majority of the time. Informal care
included daily time spent on glucose control, insulin admin-
istration, special food preparation, and monthly time spent
on healthcare visits and travelling to health centers, adminis-
trative tasks and diabetes surveillance, both by the primary
caregiver and by other caregivers.
A conservative approach was taken regarding the maxi-
mum number of caregiving hours per patient that was
allowed for analysis. This approach responds to the notion
that when caregiving time is not censored, a joint-
production bias may arise, as it will often be the case that part
of the time people spend on caregiving can be spent on other
simultaneous tasks such as housework or leisure [19]. We
used a limit of 8 h of caregiving time per day per caregiver
(primary caregiver or ‘‘other caregivers”) as the baseline
(when the care time reported per caregiver type exceeded this
number of hours) and increased it to 12 and 16 h per day per
caregiver in the sensitivity analysis. This means that, at the
baseline, the total maximum number of hours that a child
may receive is 16 h per day (8 h for primary caregiver and
8 h for other caregivers).
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good method, which uses the cost of a professional caregiver
as a proxy for the time provided by informal caregivers, con-
sidering that if the later were not to provide these services,
they would have to be replaced by a professional caregiver
[19]. We used the official hourly wage of a professional care-
giver provided by the Ministry of Health and Social Policies
as a proxy for the hourly cost of informal care [20].
Other non-healthcare costs (out of pocket expenditure on
transportation, special food, and sports activities) were
directly provided by the caregiver0s questionnaire.
3.5. Empirical analysis
Based on the general consensus about level of glycemic con-
trol in pediatric populations [21], we estimated costs accord-
ing to different levels of HbA1c, considering a cut point of
<7.5% (<58 mmol/mol) vs. 7.5% (58 mmol/mol). We ana-
lyzed whether costs vary significantly depending on HbA1c
level and the existence of diabetes related complications
and comorbidities, using gender and age of patients as con-
trol variables. When the distribution of costs was markedly
asymmetrical and very different from a Normal distribution,
multivariate regression analysis by Generalized Linear Model
(GLM) was implemented using a Gamma link function due to
the similarity with the distribution observed in the cost data
[22–24].
4. Results
A total of 275 questionnaires were collected, 26 of whomwere
excluded because of incomplete information for calculating
all the resources identified. The valid sample for analysis
amounted to 249 (90.5% of all). The main characteristics of
our sample are shown in Table 1.
4.1. Healthcare utilization
Analysis of healthcare resource utilization showed that the
patients made an average of 3.04 public primary care visits
per year (0.06 to general practitioner, 1.41 to general pediatri-
cian and 1.56 to nurse -non-diabetes education purpose-),
3.35 visits to diabetes educator nurses, and 5.45 visits to pub-
lic specialists (including endocrinologists, pediatricians, and
other). According to the type of insulin used by children,
53.3% were rapid-acting insulin, 40.8% were long-acting,
3.6% biphasic and 2.4% intermediate-acting. Most of the insu-
lin consumption was an analog origin (90.8%). Overall, 99.2%
of the children required tests or examinations, 12.4% used
insulin pumps (standard criteria for prescribing insulin
pumps are: children over the age of 2, with frequent severe
hypoglycemic events, and/or who, in spite of having received
optimal diabetes education on insulin multi-dose therapy and
adequate medical follow-up, have not yet achieved an ade-
quate metabolic control), 6.8% used CGM systems in the past
year, 92.4% did not require hospitalization during the entire
12-month period, and 7.6% were admitted once or more times
due to diabetes related problems (the mean number of annual
hospital admissions per patient who was hospitalized was1.4). Emergency care was provided at least once to 20.48% of
total patients: 6.02% in primary care emergency services,
16.87% in hospital emergency departments, and 2.01% in
medical transport (ambulance) in the form of on-site emer-
gency intervention.
4.2. Non-healthcare resources involved
With regard to other resources, 62.1% of patients received
special food and 38.0% incurred in expenditures related to
sports activities due to their disease (i.e. the caregivers
reported enrolling their child in paid activities such as swim-
ming, football, dance, etc., as part of type 1 diabetes control).
As expected in children, informal care was required by 100%
of the patients. In 35% of the cases one single caregiver was
identified and in the remaining 65% more than one caregiver
was identified. In 99% of the cases, the primary caregiver was
the child0s mother or father. In the base case, the total average
time of caregiving provided by all caregivers was 33 h per
week.
4.3. Costs assessment
The estimated average annual cost per patient in 2014 was
€27,274 (Table 2). Annual average costs have an inverted U-
shaped depending on the age of the child: 31,040€ for children
1 to 5 years old vs. 33,090€ for children 6–11 (p < 0.05), vs.
21,291€ for children 12–17 years of age (p < 0.05); but do not
significantly differ by center size (these results not shown in
tables). Direct non-healthcare costs represented the largest
proportion, with 85.1% of the total average cost per patient
(€23,204). Average direct healthcare costs were estimated in
€4070 (14.9% of total costs). The most important categories
of direct healthcare costs were medical material and supplies,
which accounted for almost 50% of healthcare costs and
7.46% of total costs, followed by outpatient and primary
healthcare visits (20.67% of direct healthcare costs and
3.08% of total costs) and insulin (14.9% of healthcare costs
and 2.12% of total costs). The most relevant category of direct
non-healthcare cost was informal care, with an average cost
of €22,618 (97.47% of direct non-healthcare cost and 82.93%
of total costs) (Table 2). The cost related to the time spent
on diabetes care by primary caregivers represented 74% of
direct non-healthcare cost and 61% of total costs. Fig. 1 shows
the distribution of direct healthcare and non-healthcare costs
in terms of percentage over total costs, and percentage over
their own cost category.
Depending on the scenario chosen to assess informal care
(maximum admitted caregiving time set at 8, 12 and 16 h per
caregiver), the estimated mean annual cost ranged from
€27,274 (base case) to €31,058 (scenario 2) and €33,056 (sce-
nario 3) (Table 3).
Direct healthcare cost differences between patients with
HbA1c 7.5% (58 mmol/mol; €4704) and patients with <7.5%
(<58 mmol/mol; €3616) were statistically significant (p < 0.01).
After controlling for age and gender, we found significant dif-
ferences in the costs of insulin, hospitalization, emergency ser-
vices, and the total direct healthcare costs of these two patient
groups. In all these categories, a level of HbA1c 7.5%
(58 mmol/mol) was associated with higher costs. Non-
Table 1 – Sample characteristics (patients included in the costs analysis n = 249, unless specifically mentioned) Mean (SD).
Patients characteristic HbA1c < 7.5% (<58 mmol/mol)
(n = 145)
HbA1c  7.5%
(58 mmol/mol) (n = 104)
Absen e of CC
(n = 19 )
Presence of CC
(n = 52)
Full sample
(n = 249)
Patient age 10.51 (3.84) 11.78 (3.83) p < 0.01 10.78 .96) 12.03 (3.40) 11.04 (3.88)
Age at time of diagnosis 5.34 (3.62) 5.90 (3.65) 5.41 (3 1) 6.19 (3.69) 5.58 (3.64)
Sex (% of males) 53.10% 52.88% 55.84% 42.31% 53.01%
Hba1C% 6.82 (0.43) 8.26 (0.89) p < 0.001 7.35 (0 2) 7.68 (1.36) 7.42 (0.97)
[mmol/mol] [51.1 (4.6)] [66.8 (9.7)] [56.9 ( 0)] [60.5 (14.9)] [57.7 (10.6)]
Number of hypoglycemic episodes in the last month 12.55 (8.69) 10.22 (11.29) p < 0.01 11.28 .85) 12.69 (13.22) 11.58 (9.91)
Number of severe hypoglycemic episodes in the last
12 months
0.11 (0.37) 0.11 (0.46) 0.09 (0 3) 0.17 (0.61) 0.11 (0.41)
Caregiver0s age (n = 235) 42.36 (6.32) 43.24 (6.06) 42.50 .19) 43.54 (6.32) 42.72 (6.22)
Total informal care hours per week (primary caregiver
plus other caregivers)a
34.12 (30.16) 31.37 (27.81) 33.39 9.76) 31.38 (27.08) 32.97 (29.18)
Total informal care hours per week (primary caregiver
plus other caregivers)b
39.90 (41.28) 36.51 (36.25) 39.12 9.85) 36.11 (37.01) 38.49 (39.22)
Total informal care hours per week (primary caregiver
plus other caregivers)c
43.29 (48.34) 38.77 (40.54) 42.37 6.39) 37.73 (40.65) 41.40 (45.21)
Informal care hours per week – primary caregivera 24.41 (19.87) 24.23 (20.91) 24.36 0.52) 24.22 (19.48) 24.33 (20.27)
Informal care hours per week - primary caregiverb 29.05 (28.16) 29.02 (29.01) 29.27 8.95) 28.13 (26.76) 29.04 (28.46)
Informal care hours per week - primary caregiverc 32.22 (34.96) 31.27 (33.91) 32.37 5.42) 29.76 (30.76) 31.82 (34.46)
Informal care hours per week – other caregiversa 9.71 (15.59) 7.13 (12.51) p = 0.02 9.03 (1 .9) 7.15 (12.45) 8.64 (14.42)
Informal care hours per week – other caregiversb 10.85 (19.34) 7.49 (14.12) p = 0.02 9.84 (1 .79) 7.96 (15.94) 9.45 (17.41)
Informal care hours per week – other caregiversc 11.07 (20.24) 7.49 (14.12) p = 0.02 10.00 8.52) 7.96 (15.94) 9.57 (18.00)
SD: Standard Deviation; CC: complications and/or comorbidities related to type 1 diabetes.
a Informal caregiving censured to a maximum of 8 h per day (base case).
b Informal caregiving censured to a maximum of 12 h per day.
c Informal caregiving censured to a maximum of 16 h per day.
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Table 2 – Average costs per patient (EUR year 2014) (n = 249).
Costs categories (bold type) and subcategories Mean (SD) % over subcategorya % over total costsb
Direct healthcare cost
Medication: insulin (measured through average daily
dose used, included in subtotal costs)
577.41 (370.07) 14.19% 2.12%
Medication: insulin (measured through vials and
pens collected from the pharmacy, not included in
subtotal costs)
819.59 (676.86) – –
Medication: other drugs 18.14 (19.56) 0.45% 0.07%
Tests 57.59 (40.63) 1.41% 0.21%
Outpatient and primary health care visits 841.39 (1243.33) 20.67% 3.08%
Hospitalization due to type 1 diabetes related
problems
452.75 (2074.34) 11.12% 1.66%
Medical material and supplies (insulin pumps, CGM
systems, glucose meters, lancets, blood strips, and
other glucose control material)
2034.70 (1550.58) 49.99% 7.46%
Emergency services 88.06 (318.67) 2.16% 0.32%
Direct healthcare cost subtotal 4070.08 (3223.77) 100.00% 14.92%
Direct non-healthcare cost
Non healthcare transportation 63.15 (150.50) 0.27% 0.23%
Special food 423.78 (661.19) 1.83% 1.55%
Physical activities 99.47 (205.40) 0.43% 0.36%
Caregiver’s time costs (informal care) 22617.8 (20015.85) 97.47% 82.93%
Primary caregiver 16691.77 (13906.43) 73.80% 61.20%
Other caregivers 5926.02 (9891.07) 26.20% 21.73%
Direct non-healthcare cost subtotal 23204.21 (20224.6) 100.00% 85.08%
Total cost (Direct healthcare plus direct non-healthcare
costs)
27274.29 (20713.61) 100.00%
SD: Standard Deviation.
a Percentage over corresponding cost subcategory.
b Percentage over TOTAL COST (Direct healthcare plus direct non-direct healthcare costs).
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(indicating no significant differences in the caregiving time
received by the patients), nor did total costs (Table 4). Table 4
also compares the average costs per patient depending on
whether the child experienced any type of diabetes related
complication and/or comorbidity (CC) or not (in this analysis
CCs includedketosiswithoutacidosis, ketoacidosis, dawnphe-
nomenon, retinopathy, nephropathy and peripheral neuropa-
thy). Overall, 52 patients (20.9%) suffered from some kind of
CC during the 12-month period and the remaining 197 patients
did not report to experience any type of CC. Patients without
CCs had lower average direct healthcare costs than patients
with CC (€3636 vs. €5713; p < 0.001). After controlling for age
and gender, we found statistically significant differences in
the costs of tests, healthcarevisits, hospitalization, and in total
healthcare costs. As with HbA1c level, non-healthcare costs
(with the exemption of special food) and total costs showed
no statistically significant differences.
4.4. Caregiver0s lost working hours
Although we have not translated into monetary values the
labor problems reported by the principal caregivers, our
results show that 111 people (44.6% of the principal care-
givers) indicated that the care of their children had caused
them some problems at work. Of these, 26 caregivers lost anaverage of 21 working hours in the past year (3.5 h for 6 work-
ing days on average) and 42 indicated that they had missed at
least one day of work because of childcare (4.5 days loss on
average in the past year). In addition, 17 caregivers reported
having to leave their job in order to look after their children
with diabetes.
5. Discussion
To our knowledge, this is the first study that estimates the
economic impact of informal caregiving of type 1 diabetes
among pediatric patients. Also, this is the first attempt to
approximate the economic healthcare costs of type 1 diabetes
in Spain, which National Health System offers full health cov-
erage with well-developed free care at point of delivery.
The research on the economic burden of type 1 diabetes in
pediatric population is scarce in the scientific literature. Previ-
ous estimations of healthcare costs in other countries range
between €1570 and €4852 (current euros of 2014) per young
patients annually [25–29]. Our results show similar healthcare
costs but significantly higher total costs than in previous
works, as a result of considering the non-health resources
involved in patient care (particularly informal care). In addi-
tion, our results indicate that direct healthcare costs of young
people with type 1 diabetes are substantial, mainly due to the
use of medical material and supplies, healthcare visits, and
Fig. 1 – Distribution of Direct Healthcare Costs and Direct
Non-Healthcare Costs: percentage over total costs, and
percentage over same cost category.
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Spanish National Health System. Although increases in these
costs are unlikely because healthcare prices are strictly regu-
lated and negotiated in Spain, any increase in the costs of
medical supplies, healthcare visits and insulin would be likely
to have an impact on the national budget.
Our results indicate that metabolic control is relatively
good among children and adolescents, with 60% of children
having an HbA1c level under 7.5%. To our knowledge this is
the first study that estimates average HbA1c levels at the
national level in the pediatric population in Spain. AccordingTable 3 – Sensitivity analysis of the average costs per patient.
Base
Mea
1. Direct healthcare cost 4070
2. Direct non-healthcare cost other than informal care 586.4
3. Caregiver’s time costs (informal care) 2261
3.1. Primary caregivers 1669
3.2. Other caregivers 5926
4. Direct non-healthcare cost (2 + 3) 2320
5. Total cost (1 + 4) 2727
a Informal caregiving censured to a maximum of 8 h per day (base case)
b Informal caregiving censured to a maximum of 12 h per day.
c Informal caregiving censured to a maximum of 16 h per day.to our estimates, a poor glycemic control of the disease
(HbA1c 7.5% or 58 mmol/mol) is associated with a 28%
increase in the direct healthcare costs (€4704 per patient vs.
€3616 for patients with HbA1c <7.5% or 58 mmol/mol). The
relationship between poor glycemic control and higher
healthcare costs among children with diabetes has also been
found in previous studies [26–29]. This relationship is not
exclusive to children with type 1 diabetes, as it has been also
confirmed for adults with type 1 or type 2 diabetes [30–32].
Aagren (2011) found that a 1-percentage-point increase in
HbA1c levels will, on average, lead to a 6.0% and 4.4% increase
in diabetes-related medical costs for type 1 and type 2 dia-
betes, respectively [30].
We also proved that, in line with other studies, the exis-
tence of acute and chronic CC related to diabetes (ketosis
without acidosis, ketoacidosis, dawn phenomenon, retinopa-
thy, nephropathy, peripheral neuropathy, hypothyroidism
and celiac disease) increases direct healthcare costs. Indeed,
those patients who suffered diabetes related CC during the
considered period consumed healthcare resources valued at
€5713, which is 57% higher than the average healthcare cost
of patients without CC (€3636). The 1-year prevalence
approach and the retrospective nature of our study impedes
considering the long-term effects of chronic complications,
which are considered the most harmful and costly [33]. Of
course, the fact that this study focuses on pediatric popula-
tion, in which the evolution of the disease is shorter than in
the adult population, can partially explain the relatively low
prevalence of CC compared to adults.
One of the strongest findings of our paper is the estimation
of informal care costs associated with type 1 diabetes.
Although the estimation of informal care is uncommon in
cost of diabetes studies, the growing scientific literature on
this subject shows the relevance of this social resource in
the case of many diseases and injuries [34–36]. To our knowl-
edge, this is the first study that estimates the economic
impact of informal caregiving among pediatric type 1 diabetes
patients. Our results show that, from a social perspective, the
costs of informal care far exceed direct healthcare expendi-
ture. According to the average time of care provided by the
patient’s environment, the cost of informal care amounts to
an average of €22,618 per patient per year.
In our analysis, we censored the maximum number of
hours of caregiving time using three different scenarios (8 h,casea Scenario 2b Scenario 3c
n (SD) Mean (SD) Mean (SD)
.08 (3223.77) 4070.08 (3223.77) 4070.08 (3223.77)
1 (733.81) 586.41 (733.81) 586.41 (733.81)
7.8 (20015.85) 26401.79 (26903.78) 28399.17 (31013.19)
1.77 (13906.43) 19918.28 (19523.88) 21829.45 (23637.02)
.02 (9891.07) 6483.505 (11938.85) 6569.717 (12346.42)
4.21 (20224.60) 26988.2 (27079.81) 28985.58 (31177.96)
4.29 (20713.61) 31058.27 (27475.44) 33055.66 (31505.76)
.
Table 4 – Average costs per patient by HbA1c level and in the presence or absence of type 1 diabetes related complications and/or comorbidities (CC). (EUR year 2014) (n = 249).
HbA1c level In the presence or absence of type 1 diabetes related CC
HbA1c < 7.5%
(<58 mmol/mol)
Mean (n = 145)
HbA1c  7.5%
(58 mmol/mol)
Mean (n = 104)
Differences of meansa (CI) Adjusted differences
of meansb (CI)
Absence of CC
Mean (n = 197)
Presence of
CC Mean (n = 52)
Differences of
meansc (CI)
Adjusted differences
of meansb (CI)
Direct health care cost
Medication: insulin 538.89 631.10 92.21 (0.92 to 185.35) 41.65 (0.45–82.84) 560.79 640.38 79.59 (33.83 to 193.02) 25.92 (45.65 to 97.51)
Medication: other drugs 16.69 20.16 3.47 (1.47 to 8.41) 4.48 (0.44 to 9.41) 17.28 21.42 4.13 (1.86 to 10.13) 2.41 (4.41 to 9.23)
Tests 55.01 61.18 6.17 (4.10 to 16.44) 4.33 (5.93 to 14.61) 54.21 70.36 16.14 (3.81–28.48) 15.67 (1.53–29.82)
Outpatient and primary health
care visits
790.07 912.95 122.88 (192.05 to 437.82) 109.82 (181.72 to 401.36) 751.79 1180.85 429.06 (50.28–807.83) 356.16 (57.87 to 770.19)
Hospitalization due to type 1
diabetes related problems
109.92 930.74 820.82 (304.91–1336.73) 798.70 (274.72–1322.68) 184.36 1469.54 1285.17 (667.55–1902.78) 1259.27 (630.21–1888.34)
Medical material and supplies 2059.33 2000.37 58.96 (452.13 to 334.20) 9.23 (391.45 to 409.91) 2012.09 2120.38 108.29 (368.62 to 585.21) 78.69 (435.71 to 593.11)
Emergency services 45.66 147.18 101.51 (21.71–181.32) 108.77 (27.82–189.72) 55.78 210.35 154.56 (58.44–250.68) 152.9 (15.75 to 321.57)
Subtotal 3615.6 4703.71 1088.11 (282.01–1894.22) 1050.53 (255.54–1845.52) 3636.32 5713.3 2076.97 (1119.79–3034.16) 1982.8 (819.02–3146.58)
Direct non health care cost
Non health care transportation 50.06 81.41 31.34 (6.61 to 69.31) 31.09 (8.63 to 70.82) 56.65 87.77 31.11 (15.03 to 77.26) 34.72 (22.05 to 91.49)
Special food 398.52 459 60.47 (107.03 to 227.98) 84.43 (84.82 to 253.68) 375.80 605.53 229.73 (28.33–431.13) 288.41 (24.71–552.11)
Physical activities 89.13 113.88 24.74 (27.25 to 76.74) 9.43 (37.12 to 56.00) 100.94 93.903 7.04 (70.23 to 56.15) 2.94 (66.51 to 60.61)
Caregiver’s time costs
(informal care)
23406.01 21518.86 1887.15 (6957.75 to 3183.45) 406.75 (5080.87 to 4267.36) 22906.23 21525.09 1381.13 (7537.52 to 4775.25) 2656.41 (3196.19 to 8509.03)
Primary caregivers 16740.75 16623.48 117.27 (3643.97 to 3409.43) 607.47 (2673.67–3888.61) 16711.26 16617.94 93.32 (4372.27 to 4185.63) 3028.15 (1250.19 to 7306.49)
Other caregivers 6665.25 4895.37 1769.88 (4268.47 to 728.71) 1031.53 (641.80 to 2704.86) 6194.97 4907.15 1287.81 (4326.99 to 1751.35) 577.42 (2586.07 to 1431.21)
Subtotal 23943.73 22173.15 1770.57 (6894.83 to 3353.67) 198.86 (4942.68 to 4526.95) 23439.64 22312.3 1127.33 (7348.78 to 5094.11) 2925.67 (3009.76 to 8861.11)
Total cost 27559.33 26876.87 682.45 (5934.83 to 4569.91) 1036.86 (3960.06 to 6033.77) 27075.97 28025.61 949.64 (5422.76 to 7322.05) 4134.79 (2206.13 to 10475.73)
CI: confidence interval.
a Positive values indicate that children with HbA1c 7.5% consumed significantly more resources than children with HbA1c <7.5%.
b Adjusted differences of means by sex and age using General Linear Models.
c Positive values indicate that children with CC consumed significantly more resources than children without CC.
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overestimates of time devoted to care where joint production
activities may be performed [37]. Censorship in our study
affects only 5% of caregivers. In the remaining caregivers
(95%), the valuation was made on the amount of time caring
for the different activities mentioned by the surveyed care-
givers. However, as can be seen, the cost of informal care
ranges between 22,618 euros (censorship 8 h per day), 26,402
euros (censorship 12 h) and 28,399 euros (censorship 16 h
per day). This implies that a small number of caregivers
referred a large amount of time devoted to diabetes care,
which significantly influences the estimated cost of informal
care. Future research could study whether the costs of infor-
mal care vary depending on the type of revelation system
used for collecting time devoted to care. For example, com-
bining questionnaires (recall method, which was used in
our study) with a dairy where caregivers carefully indicate
the diabetes care related tasks performed and the time spent
on each of them, may result in a more accurate calculation of
the real time spent on caregiving activities and therefore on a
more precise estimation of the costs of informal care.
Our study adopts the societal perspective. However, it does
not imply that all relevant costs have been included in the
analysis. The productivity losses of the primary caregivers,
who often need to reduce working hours because of the time
they need to spend as the child0s caregiver, is one of them.
However, in order to avoid assigning double costs to the time
devoted to diabetes care productivity losses have not been
included. There are several methods of valuation of informal
care that have been used in the literature [19]. In this work, we
have estimated the informal care using the proxy good
method or market cost method where time spent on informal
care is valued as the (labor) market prices of a close market
substitute.
A further analysis of labor problems of caregivers exceeds
the scope of this article. However, it is a very important line of
research for future work, which would help shed light into the
real impact of diabetes in pediatric patients. Similarly,
although we have not made a monetary valuation, lost school
time attributable to diabetes for children is a very relevant
variable from a social point of view. Our estimates show that
school-age children lost an average of 5.61 annual school days
[4.04 in children with Hba1c <7.5% (<58 mmol/mol) and 7.83
with Hba1c 7.5% (58 mmol/mol)]. According to Tao et al.
(2010), children with type 1 diabetes miss school 3.7 days
yearly, 9.3 times more than children who do not have diabetes
[38]. Therefore, the socioeconomic impact of type 1 diabetes
goes beyond the figures estimated in our study. Our analysis
can be considered as a useful first step, since it is the first
work that shows the cost of type 1 diabetes in Spanish chil-
dren. However, it is necessary to deepen the analysis of other
social costs that help to reveal the true impact of type 1 dia-
betes on the wellbeing of children and caregivers.
Additionally, it must be recognized that an ideal study
would follow a prospective longitudinal cohort of type 1 dia-
betes pediatric population where the long-term impact of
the disease’s complications over health can be taken into
account. However, this type of study was beyond our means.
In spite of its limitations, we believe that this study repre-
sents the most complete and realistic costing of the burden oftype 1 diabetes patients performed to date in Spain. The main
strength of the study lies in the bottom-up approach to cost-
ing. In addition, the costs were estimated for a period of
1 year, therefore they provide an accurate picture of the
medium-term burden of type 1 diabetes.
As is the case with most chronic prevalent conditions
associated to acute and chronic complications, type 1 dia-
betes exerts a great impact on public health resources, which
justifies the attention received from health authorities and
society in general [39]. The control and consequences of the
disease also result in relevant costs to patients and caregivers.
Because decision-makers consider information about the
financial impact of diseases to be a useful input for program
planning, the governments of many countries continue to
encourage researchers to carry out cost-of-illness analysis
[40,41].
In conclusion, the results from the CHRYSTAL study high-
light the importance of analyzing the economic conse-
quences of type 1 diabetes from a societal perspective. Our
results provide insights into the distribution of the costs of
type 1 diabetes and the impact of this disease on national
expenditures for healthcare, and show that healthcare and
social costs of type 1 diabetes pediatric patients are consider-
able in Spain.We identified statistically significant differences
in healthcare costs associated with HbA1c level and with the
presence of complications. Our results also suggest that any
program, strategy or policy on health promotion and care
for type 1 diabetes pediatric patients cannot overlook the
importance of informal support networks. A clear under-
standing of the current patterns of resource use and costs
in type 1 diabetes patients is needed from the social perspec-
tive in order to inform health services planning appropriately.Conflict of interest
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